This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Colorectal cancer	Jumonji domain containing 6 (JMJD6)	<p>Mouse and <i>in vitro</i> studies suggest inhibiting JMJD6 signaling could be useful for treating colon cancer. <i>In vitro</i>, JMJD6 acted as an α-ketoglutarate- and Fe(II)-dependent lysyl hydroxylase, which catalyzes hydroxylation of the tumor suppressor p53 to decrease its transcriptional activity. In human colon cancer cell lines and a mouse xenograft model of colorectal cancer, siRNA against <i>Jmjd6</i> increased p53 activity and apoptosis and decreased tumor growth compared with control siRNA. Next steps could include screening for inhibitors of JMJD6.</p> <p>SciBX 7(17); doi:10.1038/scibx.2014.489 Published online May 1, 2014</p>	Patent and licensing status unavailable	<p>Wang, F. <i>et al. PLoS Biol.</i>; published online March 25, 2014; doi:10.1371/journal.pbio.1001819 Contact: Yongfeng Shang, Peking University Health Science Center, Beijing, China e-mail: yshang@hsc.pku.edu.cn Contact: Luyang Sun, same affiliation as above e-mail: luyang_sun@hsc.pku.edu.cn</p>